Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Inclusion Criteria

• •Diagnosis of HS for at least 6 months prior to screening visit.
• •Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits:
• •* A total AN count of at least 4, with no draining tunnels AND
• •* Affecting at least 2 distinct anatomical areas
• •Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period.
• •Agreement to NOT use topical antiseptics, including washes and leave-on products on the areas affected by HS lesions during the vehicle-controlled period and Weeks 16 to 20 of the extension period.